WO2001040275A3 - Peptides that stabilize protein antigens and enhance presentation to cd8+ t cells - Google Patents

Peptides that stabilize protein antigens and enhance presentation to cd8+ t cells Download PDF

Info

Publication number
WO2001040275A3
WO2001040275A3 PCT/US2000/033027 US0033027W WO0140275A3 WO 2001040275 A3 WO2001040275 A3 WO 2001040275A3 US 0033027 W US0033027 W US 0033027W WO 0140275 A3 WO0140275 A3 WO 0140275A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
peptides
protein antigens
stabilize protein
enhance presentation
Prior art date
Application number
PCT/US2000/033027
Other languages
French (fr)
Other versions
WO2001040275A2 (en
Inventor
Roger J Kurlander
Elizabeth Chao
Janet Fields
Original Assignee
Us Health
Roger J Kurlander
Elizabeth Chao
Janet Fields
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Roger J Kurlander, Elizabeth Chao, Janet Fields filed Critical Us Health
Priority to AU20626/01A priority Critical patent/AU2062601A/en
Publication of WO2001040275A2 publication Critical patent/WO2001040275A2/en
Publication of WO2001040275A3 publication Critical patent/WO2001040275A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to compositions and methods for stabilizing an antigen and enhancing its presentation to CD8+ T cells. Novel biological tools, therapeutics, and prophylactics comprising a hydrophobic fragment of the bacterial protein lemA and methods of use of the foregoing are provided for the study, treatment, and prevention of human disease.
PCT/US2000/033027 1999-12-06 2000-12-06 Peptides that stabilize protein antigens and enhance presentation to cd8+ t cells WO2001040275A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20626/01A AU2062601A (en) 1999-12-06 2000-12-06 Peptides that stabilize protein antigens and enhance presentation to CD8+ T cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16922799P 1999-12-06 1999-12-06
US60/169,227 1999-12-06

Publications (2)

Publication Number Publication Date
WO2001040275A2 WO2001040275A2 (en) 2001-06-07
WO2001040275A3 true WO2001040275A3 (en) 2002-03-21

Family

ID=22614723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033027 WO2001040275A2 (en) 1999-12-06 2000-12-06 Peptides that stabilize protein antigens and enhance presentation to cd8+ t cells

Country Status (2)

Country Link
AU (1) AU2062601A (en)
WO (1) WO2001040275A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609083D0 (en) 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003156A1 (en) * 1991-07-26 1993-02-18 Board Of Regents, The University Of Texas System Sequence for stabilizing proteins in bacteria protein stabilization sequence
WO1997025070A2 (en) * 1996-01-08 1997-07-17 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
WO1999023229A1 (en) * 1997-10-30 1999-05-14 Cornell Research Foundation, Inc. A method of inhibiting an immune response to a recombinant vector
US5945513A (en) * 1992-09-04 1999-08-31 Bristol-Myers Squibb Fusion proteins comprising gp39 and CD8

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003156A1 (en) * 1991-07-26 1993-02-18 Board Of Regents, The University Of Texas System Sequence for stabilizing proteins in bacteria protein stabilization sequence
US5945513A (en) * 1992-09-04 1999-08-31 Bristol-Myers Squibb Fusion proteins comprising gp39 and CD8
WO1997025070A2 (en) * 1996-01-08 1997-07-17 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
WO1999023229A1 (en) * 1997-10-30 1999-05-14 Cornell Research Foundation, Inc. A method of inhibiting an immune response to a recombinant vector

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NATARAJ, CHANDRASEKARAN ET AL: "H2M3wt-restricted, Listeria monocytogenes-immune CD8 T cells respond to multiple formylated peptides and to a variety of Gram-positive and Gram-negative bacteria", XP002173000, retrieved from STN Database accession no. 128:203884 CA *
INT. IMMUNOL. (1998), 10(1), 7-15, 1998 *
N M CHIU ET AL.: "The selection of M3-restricted T cells is dependent on M3 expression and presentation of N-formylated peptides in the thymus", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 190, no. 12, 20 December 1999 (1999-12-20), TOKYO, JP, pages 1869 - 1878, XP002172998, ISSN: 0022-1007 *
R KURLANDER ET AL.: "The adjacent flanking region plays a critical role in facilitating the presentation of Listeria monocytogenes product lemA to H2 M3wt-restricted peptide-specific murine CD8 cells", JOURNAL OF IMMUNOLOGY, vol. 163, no. 12, 15 December 1999 (1999-12-15), BALTIMORE US, pages 6741 - 6747, XP002172999 *

Also Published As

Publication number Publication date
AU2062601A (en) 2001-06-12
WO2001040275A2 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004043361A3 (en) Compositions and methods for the treatment of natural killer cell related diseases
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004024068A3 (en) Novel composition and methods for the treatment of immune related diseases
WO2005012479A3 (en) Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
IL163812A (en) Immunizing composition, antigenic product and isolated antigenic peptide for inducing an immune response against beta-secretase cleavage site of amyloid the precursor protein
AU2003256912A1 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
WO2004037175A3 (en) Compositions and methods for treating human papillomavirus-mediated disease
WO2005051988A3 (en) Compositions and methods for the treatment of systemic lupus erythematosis
WO2004011605A3 (en) Hybrid protein methods and compositions
WO2004081199A3 (en) Novel compositions and methods for the treatment of immune related disease
EP1028754A4 (en) Prevention of immunoreactivity by depleting or inhibiting antigen presenting cells
WO2002047613A3 (en) Immunogenic cancer peptides and uses thereof
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
WO2001040275A3 (en) Peptides that stabilize protein antigens and enhance presentation to cd8+ t cells
MXPA04001986A (en) Compositions and methods for the treatment of immune related diseases.
WO2004031354A3 (en) Human sarcoma-associated antigens
WO2004043397A3 (en) Compositions and methods for the treatment of rheumatoid arthritis
WO2004015390A3 (en) Lung cancer target proteins and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP